Emergent BioSolutions Reports Q3 2026 Net Loss Amid Revenue Decline and Guidance Revision
Emergent BioSolutions (EBS) reported a challenging third quarter for 2026, with total revenues falling 52% to $110.0 million. The decline was primarily attributed to the timing of medical countermeasure deliveries and significant pressure in the naloxone market, where NARCAN sales dropped 42%. Consequently, the company swung from a net income of $51.2 million in the prior year to a net loss of $32.7 million this quarter. Despite these headwinds, management is focusing on long-term restructuring and debt reduction. The company successfully reduced net debt by 55% since year-end 2023 and expects $40 million in annualized cost savings from ongoing restructuring efforts. However, due to delivery timing uncertainties, the company has lowered its full-year revenue guidance to a range of $600 million to $645 million.
Tickers: $EBS
Topics: Financial Performance Medical Countermeasures Naloxone Sales Net Loss Revenue Decline